期刊
NEUROSCIENCE LETTERS
卷 725, 期 -, 页码 -出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.neulet.2020.134900
关键词
Neuromuscular disease; Myasthenia gravis; Spasticity; Endocannabinoids; Neuromuscular junction; Anandamide; Dihydropyridine receptor; L-type calcium channels
资金
- University of Sydney Bridging Grant Scheme
- Program for Guangdong Introducing Innovating and Entrepreneurial Teams [2014ZT05S020]
- China Postdoctoral Science Foundation [237400]
- Lambert Initiative for Cannabinoid Therapeutics
Endocannabinoids play important roles in regulating CNS synaptic function and peripheral metabolism, but cannabinoids can also act acutely to modulate contraction strength in skeletal muscle. Nerve terminals and the skeletal muscle sarcolemma express components of the cannabinoid signaling system. Endocannabinoids, N-arachidonylethanolamine (anandamide, AEA) and 2-arachidonoyl-glycerol (2-AG), are produced by skeletal muscle. They may be involved in the acute regulation of neuromuscular transmission, by adjusting the parameters for quantal acetylcholine release from the motor nerve terminal. Downstream of neuromuscular transmission, cannabinoids may also act to limit the efficiency of excitation-contraction coupling. Improved understanding of the distinct signaling actions of particular cannabinoid compounds and their receptor/transduction systems will help advance our understanding of the role of endocannabinoids in skeletal muscle physiology. Cannabinoids might also offer the potential to develop new pharmacotherapeutics to treat neuromuscular disorders that affect muscle strength.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据